IPO fever is sweeping through the psychedelics space.

A $225 billion treatment market is badly in need of new therapies. Here is the roadmap for investors to capitalize on this opportunity.

Compass Pathways has upsized its IPO financing to $127.5 million, at an offering price of $17.00 per American Depositiry Share (ADS).

Compass has boosted its IPO financing by roughly 20% AND increased the unit price — signalling strong interest in the psychedelic space.

A study by researchers at Australia’s Chris O’Brien Lifehouse found a 14-25 percent reduction in chemotherapy side effects, such as nausea and vomiting, in patients who used cannabis capsules containing a 1:1 THC to CBD ratio, 9News reports.

The campaign behind an initiative to legalize marijuana in Arizona has their work cut out for them in the coming weeks, as a new poll shows that just a slim majority of voters support the ballot measure.

Canada stands out as the premier destination for psychedelic drug companies.

Champignon Brands continues to work with the BC Secutiries Commission to complete its disclosure review.

Functional mushrooms are a large-and-growing health supplements market with synergies to psychedelics operations.

With the launch of a nationwide get-out-the-vote campaign this week, marijuana legalization advocates hope to muster cannabis consumers as a powerful voting bloc this November and maintain that momentum for elections to come.